A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation

Current Medical Research and Opinion

Volumn 29, Issue 2, 2013, Pages 149-160

  Johnston, Jeffrey M ^a   Shiff, Steven J ^b   Quigley, Eamonn M M ^c  

^a IRONWOOD PHARMACEUTICALS INC   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c University College Cork and INFANT Centre   (Ireland)

Author keywords

Abdominal discomfort; Abdominal pain; Bowel movement; Irritable bowel syndrome; Linaclotide; Visceral hypersensitivity

Indexed keywords

ALVERINE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ARACHIS OIL; BISACODYL; BULKING AGENT; CHLORIDE CHANNEL STIMULATING AGENT; DICYCLOVERINE; DOCUSATE SODIUM; GLYCEROL; GUANYLATE CYCLASE ACTIVATOR; LACTULOSE; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; MEBEVERINE; METHYLCELLULOSE; OTILONIUM BROMIDE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SCOPOLAMINE; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SIMETHICONE; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; BLOATING; CHRONIC PAIN; COCHRANE LIBRARY; CONSENSUS DEVELOPMENT; CONSTIPATION; DEFECATION; DEFECATION URGENCY; DIARRHEA; DIETARY FIBER; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLATULENCE; HEADACHE; HUMAN; HYPERALGESIA; INTESTINAL SECRETION; INTESTINE TRANSIT TIME; IRRITABLE BOWEL SYNDROME WITH CONSTIPATION; IRRITABLE COLON; LIFESTYLE MODIFICATION; LOW DRUG DOSE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; VIRAL GASTROENTERITIS; VISCERAL PAIN;

ABDOMINAL PAIN; CONSTIPATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL SECRETIONS; IRRITABLE BOWEL SYNDROME; MALE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84872235011     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.754743     Document Type: Review

References (71)

1. Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004;18:613-31
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
3. Hungin APS, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment Pharmacol Ther 2003;17:643-50
4. Saito Y, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-15
5. Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2007;103:1229-39
6. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-35
7. Quigley E, Fried M, Gwee KA, et al. Irritable bowel syndrome: a global perspective. World Gastroenterology Organisation Global Guideline, 2009. Available at: http://www.worldgastroenterology.org/assets/downloads/en/pdf/ guidelines/20-irritable-bowel-syndrome.pdf [Last accessed 9 August 2012]
8. Linzess [prescribing information]. St. Louis, MO, USA: Forest Laboratories Inc., 2012
9. European Medicines Agency. Constella: EPAR summary for the public. 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary- for-the-public/human/002490/WC500135625.pdf [Last accessed 6 December 2012]
10. Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003;98:2454-9
11. Mertz H. Review article: visceral hypersensitivity. Ailment Pharmacol Ther 2003;17:623-33
12. Drossman DA, Morris C, Hu Y, et al. Further characterization of painful constipation (PC). J Clin Gastroenterol 2008;42:1080-8
13. Food and Drug Administration. Guidance for industry. Irritable bowel syndrome-clinical evaluation of products for treatment. 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM205269.pdf [Last accessed 1 August 2012]
14. European Medicines Agency. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. 2003. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003187.pdf [Last accessed 1 August 2012]
15. European Medicines Agency. Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2012/06/WC500128217.pdf [Last accessed 13 November 2013]
16. National Institute for Health and Clinical Excellence. Clinical practice guideline. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. Available at: http://guidance. nice.org.uk/CG61/Guidance/pdf/English [Last accessed 13 September 2012]
17. Xifaxan [prescribing information]. Raleigh, NC, USA: Salix Pharmaceuticals Inc., 2011
18. Anaspaz [prescribing information]. Lenexa, KS, USA: B.F. Ascher & Company Inc., updated 2012
19. Bentyl [prescribing information]. Birmingham, AL, USA: Aptalis Pharma US Inc., 2012
20. Pro-Banthine [prescribing information]. Owings Mills, MD, USA: Shire US Manufacturing Inc., 2007
21. Transderm Scop [prescribing information]. Mountain View, CA, USA: Novartis Consumer Health Inc., 2006
22. Amitiza [prescribing information]. Bethesda, MD, USA: Sucampo Pharma Americais Inc., 2011
23. Amitriptyline hydrochloride [prescribing information]. Indiana, PA, USA: Remedyrepack Inc, 2010
24. Anafranil [prescribing information]. Hazelwood, MO, USA: Mallinckrodt Inc., 2011
25. Desipramine hydrochloride [prescribing information]. Little Falls, NJ, USA: Amide Pharmaceuticals Inc, 2007
26. Doxepin hydrochloride [prescribing information]. Pulaski, TN, USA: AcKARE Inc., 2012
27. Imipramine hydrocholoride [prescribing information]. Baltimore, MD, USA: Lupin Pharmaceuticals Inc., 2009
28. Nortriptyline hydrochloride [prescribing information]. Morgantown, WV, USA: Mylan Pharmaceuticals Inc., 2007
29. Protriptyline hydrochloride [prescribing information]. Roxane Laboratories Inc., 2010
30. Celexa [prescribing information]. St. Louis, MO, USA: Forest Pharmaceuticals Inc., 2011
31. Escitalopram [prescribing information]. Morgantown, WV, USA: Mylan Pharmaceuticals Inc., 2011
32. Fluoxetine [prescribing information]. Pomona, NY, USA: Barr Laboratories Inc., 2010
33. Fluvoxamine maleate [prescribing information]. Morgantown, WV, USA: Myland Pharmaceuticals Inc., 2011
34. Paroxetine hydrochloride [prescribing information]. Morgantown, WV, USA: Mylan Pharmaceuticals Inc., 2012
35. Sertraline hydrochloride [prescribing information]. Corona, CA, USA: Watson Laboratories Inc., 2007
36. Zelnorm [prescribing information]. East Hanover, NJ, USA: Novartis Pharmaceuticals Corporation, 2006
37. Layer P, Andresen V, Pehl C, et al. S3 guideline irritable bowel syndrome: definition, pathophysiology, diagnosis and therapy. Joint guideline of the German Society for Digestive and Metabolic Disease (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM). Z Gastroenterol 2011;49:237-93
38. Spanish Association of Gastroenterology, Spanish Society of Family and Community Medicine, and Cochrane Collaboration. Irritable bowel syndrome. Clinical Practice Guidelines 2005. Available at: http://www.cochrane.es/- cochrane/files/sii.pdf [Last accessed 25 September 2012]
39. Swedish Gastroenterological Association. IBS-diagnosis and treatment. Summary document. Available at: http://www.svenskgastroenterologi.se/Riktlinjer/ Riktlinjer-IBS.pdf [Last accessed 26 September 2012]
40. Oxford Centre for Evidence-based Medicine. Oxford Centre for Evidencebased Medicine-Levels of Evidence. 2009. Available at: http://www.cebm.net/index.aspx?o/1025 [Last accessed 10 October 2012]
41. Langdon SJ, Jackson CW, Whorwell PJ. Therapeutic options in irritable bowel syndrome. Br J Pharmaceut Pract 1987;March:62-4
42. Quigley EM. Probiotics in the management of functional bowel disorders: promise fulfilled? Gastroenterol Clin North Am 2012;4:805-19
43. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-6
44. Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313
45. Clavé P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:432-42
46. Wittmann T, Paradowski L, Ducrotté P, et al. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome-a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010;31:615-24
47. Ford AC, Vandvik PO. Irritable bowel syndrome. Clinical Evidence 2012;1:1-38
48. Khawam EA, Laurencic G, Malone Jr DA. Side effects of antidepressants: an overview. Clev Clin J Med 2006;73:351-61
49. Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil 2007;19:4-10
50. Rahimi R, Nikfar S, Abdollah M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci 2008;1:71-6
51. Gale JD, Houghton LA. Alpha 2 delta (a2d) ligands, gapapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome? Front Pharmacol 2011;2:1-9
52. Bradesi S, Mayer EA. Novel therapeutic approaches in IBS. Curr Opin Pharmacol 2007;7:598-604
53. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004;10:299-309
54. Hungin APS, Tack J, Mearin F, et al. The truth in IBS (T-IBS) survey-healthcare utilization and medication use among IBS patients in the USA. Am J Gastroenterol 2002;97(Suppl):S281 [abstract]
55. Hungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-75
56. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649:328-35
57. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86:760-5
58. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84
59. Castro J, Hughes P, Martin C, et al. A novel role of cyclic GMP in colonic sensory neurotransmission in healthy and TNBS-treated mice. Gastroenterology 2011;140(Suppl 1):S538 [abstract]
60. Feng B, Kiyatkin ME, La J-H, et al. Cyclic guanylate monophosphate (cGMP) attenuates responses and sensitization of mouse colorectal afferents. Gastroenterology 2012;142(Suppl 1):S698 [abstract]
61. Castro J, Harrington AM, Hughes PA, et al. Mechanism of action for linaclotide induced abdominal pain relief. Gastroenterology 2012;142(Suppl 1):S699 [abstract]
62. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
63. Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-86
64. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107:1714-24
65. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-12
66. Quigley E, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C-a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013;37:49-61
67. Spiegel BMR, Locke III R, Kurtz CM, et al. Developing benchmarks for clinically meaningful change for IBS-C symptoms using data from two phase 3 trials of linaclotide. Gastroenterology 2012;142(Suppl 1):S214 [abstract]
68. Locke GR, Chey WD, Kurtz CB, et al. Effects of linaclotide treatment on patient-reported ratings of change for symptoms of irritable bowel syndrome with constipation (IBS-C): pooled 12-week findings from two phase 2 trials. Gastroenterology 2012;142(Suppl 1):S737 [abstract]
69. Schoenfeld PS, Chey WD, Lavins BJ, et al. Linaclotide significantly improved abdominal pain compared with placebo in patients with irritable bowel syndrome regardless of baseline pain severity in two phase 3 trials. Gastroenterology 2012;142(Suppl 1):S701 [abstract]
70. Rao SS, Quigley EM, Shiff SJ, et al. Efficacy of linaclotide in improving abdominal symptoms rated as most severe by patients with irritable bowel syndrome with constipation (IBS-C). Gastroenterology 2012; 142(Suppl 1):S144 [abstract]
71. MacDougall JE, MacKinnon DP, Lavins BJ, et al. Mediation analysis supports a direct effect of linaclotide on relief of abdominal pain independent of constipation improvement. Gastroenterology 2012;142(Suppl 1):S215-16 [abstract]